Home » Topics » BioWorld Science

BioWorld Science
RSS

CureVac reports preclinical data on bivalent second-generation COVID-19 vaccine

April 22, 2022

Novel PAD4 inhibitor JBI-1044 shows strong potency for cancer treatment

April 22, 2022

Codexis and seqWell partner to accelerate commercialization of genomics workflow solutions

April 22, 2022

Discovery of novel orally bioavailable CREB inhibitor

April 22, 2022

Cocrystal Pharma's 3CL protease inhibitors to be studied by NIAID for COVID-19

April 22, 2022

JNJ-78306358, a novel bispecific antibody with HLA-G expression-dependent antitumor activity

April 22, 2022

Sunshine Lake Pharma patents new GNRHR antagonists

April 22, 2022

Janssen synthesizes new DHODH inhibitors

April 22, 2022

Asahi Kasei Pharma and Vernalis Group present new IRAK inhibitors

April 22, 2022

Cadila Healthcare patents viral nsp3 inhibitors

April 22, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.